In Vitro: The DC50 values of ARD-1676 for AR degradation in AR+ VCaP and LNCaP cell lines are 0.1 and 1.1 nM, respectively, and the IC50 values in VCaP and LNCaP cell lines are 11.5 and 2.8 nM respectively.
In Vivo: The oral bioavailability of ARD-1676 was 67%, 44%, 31%, and 99% in mice, rats, dogs, and monkeys, respectively. ARD-1676 effectively reduces AR protein levels in mouse VCaP tumor tissues and inhibits tumor growth in VCaP mouse xenograft tumor models.